The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
ORGANIZATION
JGA Issues Written Reprimand to Sawai over GMP Issues
The Japan Generic Medicines Association (JGA) has issued a written reprimand to Sawai Pharmaceutical after the generic giant was slapped with business improvement orders over its fraudulent testing of the gastritis and gastric ulcer drug Teprenone Capsules. A reprimand is…
To read the full story
Related Article
- Sawai and Kaigen Submit Biz Improvement Plans to Osaka Govt
February 14, 2024
- (Update) Sawai Slapped with Biz Improvement Order over Rigged Quality Tests
December 25, 2023
- Sawai Slapped with Biz Improvement Order over Rigged Quality Tests
December 22, 2023
- Sawai’s Misconduct Severely Undermines Credibility of Generics: Health Minister
October 25, 2023
- Sawai Fudged Quality Tests of Gastritis Drug for 8 Years, Awaiting Penalty Decision
October 24, 2023
- LDP Lawmakers Deplore Reported GMP Issues at Sawai
September 8, 2023
ORGANIZATION
- JEMA Proposing “Improved Drug” Category with Minimal Application Dossiers
March 10, 2025
- Cough Drug Asverin Tops Supply Shortage Ranking in Japan: P-Cubed Survey
March 6, 2025
- JPMA President Demands Rethink of Social Security Expenditure Cap
February 27, 2025
- People’s Trust in Pharma Industry Down to 83.9% in 2024: JPMA Poll
February 27, 2025
- Japan Pharma Lobbies Likely to Enter Yasukawa/Miyabashira Era toward FY2026 Reform
February 26, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…